Also, in Asia it is unusual for biotechs to go public at the early stage — something commonly seen in Australia.
Investments usually need to be ‘derisked’ which means Asian investors are keen on stocks which have made it through to Phase 1 or Phase 2 trials, the hurdle most biotechs fail.
It is only once the risk profile of biotechs has been reduced by getting their new drugs through these initial trials that Asian investors will look at putting money on the table.
- Forums
- ASX - By Stock
- GMV
- Ann: Response to ASX Query
Ann: Response to ASX Query, page-141
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GMV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online